Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 Alere
Inc. 
 $425,000,000 6.375% Senior Subordinated Notes due 2023 

PURCHASE AGREEMENT 

June 11, 2015 
 J.P. MORGAN SECURITIES LLC

 As Representative of the several Initial Purchasers 
 c/o 383
Madison Avenue 
 New York, New York, 10179 
 Ladies and
Gentlemen: 
 Introductory. Alere Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the
several initial purchasers named in Schedule A (the “Initial Purchasers”) $425,000,000 aggregate principal amount of its 6.375% senior subordinated notes due 2023 (the “Notes”). The Company’s obligations
under the Notes and the Indenture (as defined below) will be, jointly and severally, unconditionally guaranteed (the “Guarantees”), on a senior subordinated basis, by each of the Subsidiaries (as defined below) listed on the
signature pages hereto (collectively, the “Guarantors,” and, together with the Company, the “Issuers”). The Notes and the Guarantees are referred to herein as the “Securities.” The respective
principal amounts of the Notes to be so purchased by the several Initial Purchasers are set forth opposite their names in Schedule A hereto. The Notes are to be issued under an indenture dated as of May 12, 2009 (the “Base
Indenture”) as supplemented by a supplemental indenture (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”) to be dated as of the Closing Date (as defined below), by and
between the Issuers and U.S. Bank National Association, as Trustee (the “Trustee”). 
 J.P. Morgan Securities LLC
(“J.P. Morgan”) has agreed to act as representative of the several Initial Purchasers (in such capacity, the “Representative”) in connection with the offering and sale of the Securities. 

The Securities will be offered and sold to the Initial Purchasers pursuant to an exemption from the registration requirements under the
Securities Act of 1933, as amended (the “Securities Act”). The Issuers have prepared a preliminary offering memorandum, dated as of June 10, 2015 (the “Preliminary Offering Memorandum”), and a pricing
supplement thereto dated the date hereof (the “Pricing Supplement”). The Preliminary Offering Memorandum and the Pricing Supplement are herein referred to as the “Pricing Disclosure Package.” Promptly after the
execution of this Purchase Agreement (this “Agreement”), the Issuers will prepare a final offering memorandum dated the date hereof (the “Final Offering Memorandum”). As used herein, “Applicable
Time” is 2:50 p.m. (New York time) on June 11, 2015. Unless stated to the contrary, any references herein to the terms “Pricing Disclosure Package” and “Final Offering Memorandum” shall be deemed to refer to and
include any information filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the Applicable Time and incorporated by reference therein, and any references herein to the terms “amend,”
“amendment” or “supplement” with respect to the Final Offering Memorandum shall be deemed to refer to and include any information filed under the Exchange Act subsequent to the Applicable Time that is incorporated by reference
therein. All references in this Agreement to financial statements and schedules and other information which are “contained,” “included” or “stated” (or other references of like import) in the Pricing Disclosure Package
(including the Preliminary Offering Memorandum) or Final Offering 

 
Memorandum shall be deemed to mean and include all such financial statements and schedules and other information which are or are deemed to be incorporated by reference in the Pricing Disclosure
Package or Final Offering Memorandum, as the case may be. 
 The Initial Purchasers have advised the Issuers that the Initial Purchasers
intend, as soon as they deem practicable after this Agreement has been executed and delivered, to resell (the “Exempt Resales”) the Securities in private sales exempt from registration under the Securities Act on the terms set forth
in the Pricing Disclosure Package, solely to (i) persons whom the Initial Purchasers reasonably believe to be “qualified institutional buyers” (“QIBs”), as defined in Rule 144A under the Securities Act (“Rule
144A”), in accordance with Rule 144A and (ii) other eligible purchasers pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the Securities Act (“Regulation S”) in
accordance with Regulations S (the persons specified in clauses (i) and (ii), the “Eligible Purchasers”). 
 This
Agreement, the Notes, the Guarantees and the Indenture are hereinafter sometimes referred to collectively as the “Note Documents.” The issuance and sale of the Securities are referred to as the “Transactions.” 

The Issuers hereby confirm their respective agreements with the Initial Purchasers as follows: 

Section 1 Representations and Warranties. (i) The Issuers hereby represent and warrant to each Initial Purchaser, as of the
date of this Agreement and as of the Closing Date (as hereinafter defined) and jointly and severally covenant with each Initial Purchaser (references in this Section 1 to the “Offering Memorandum” are to (x) the Pricing
Disclosure Package in the case of representations and warranties made as of the date hereof and (y) the Final Offering Memorandum in the case of representations and warranties made as of the Closing Date), as follows: 

(a) Accuracy of Notes Documents. Neither the Pricing Disclosure Package, as of the date hereof or as of the Closing Date, nor the Final
Offering Memorandum, as of its date or (as amended or supplemented in accordance with Section 3(c), if applicable) as of the Closing Date, contains any untrue statement of a material fact or omits to state any material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Issuers make no representation or warranty with respect to information relating to the Initial
Purchasers contained in or omitted from the Pricing Disclosure Package, the Final Offering Memorandum or any amendment or supplement thereto in reliance upon and in conformity with information furnished to the Company in writing by or on behalf of
any Initial Purchaser through the Representative expressly for inclusion in the Pricing Disclosure Package, the Final Offering Memorandum or any amendment or supplement thereto, as the case may be. No order preventing the use of the Preliminary
Offering Memorandum, the Pricing Supplement or the Final Offering Memorandum, or any amendment or supplement thereto, or any order asserting that any of the transactions contemplated by this Agreement are subject to the registration requirements of
the Securities Act, has been issued or, to the Company’s knowledge, has been threatened. 
 (b) Distribution of Note Documents.
The Company (including its agents and representatives, other than the Initial Purchasers in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any
written communication that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives an “Issuer Written Communication”) other than
(i) the Pricing Disclosure Package, (ii) the Final Offering Memorandum and 

  
 -2- 

 
(iii) any Road Show (as defined herein). Each such Issuer Written Communication, when taken together with the Pricing Disclosure Package, did not, and at the Closing Date will not, contain any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(c) Class of Securities. There are no securities of the Issuers that are listed on a national securities exchange registered under
Section 6 of the Exchange Act or that are quoted in a United States automated interdealer quotation system that are of the same class, within the meaning of Rule 144A as the Securities. 

(d) The Purchase Agreement. This Agreement has been duly and validly authorized, executed and delivered by, and is a valid and binding
agreement of, each Issuer, enforceable against it in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity and the discretion of the court before which any proceeding therefor may be brought
(all such exceptions collectively, the “Enforceability Exceptions”). This Agreement conforms in all material respects to the description thereof in the Pricing Disclosure Package. 

(e) Authorization of the Indenture. The Indenture has been duly and validly authorized by each Issuer and, when the Supplemental
Indenture is duly executed and delivered by the Issuers (assuming the due authorization, execution and delivery thereof by the Trustee), the Indenture will be a legally binding and valid obligation of each such Issuer, enforceable against it in
accordance with its terms, except as the enforcement thereof may be limited by Enforceability Exceptions. The Indenture, when the Supplemental Indenture is executed and delivered, will conform in all material respects to the description thereof in
the Pricing Disclosure Package. The Base Indenture has been duly qualified under the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”). 

(f) Authorization of the Notes. The Notes have been duly and validly authorized for issuance and sale to the Initial Purchasers
by the Company and, when issued, authenticated by the Trustee, and delivered by or on behalf of the Company against payment therefor by the Initial Purchasers in accordance with the terms of this Agreement and the Indenture, the Notes will be
legally binding and valid obligations of the Company, entitled to the benefits of the Indenture and enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by the Enforceability Exceptions.
The Notes, when issued, authenticated by the Trustee and delivered by or on behalf of the Company, will conform in all material respects to the description thereof in the Offering Memorandum.  

(g) Authorization of the Guarantees. Each Guarantee has been duly and validly authorized by the applicable Guarantor and, when the
Notes are issued and delivered by or on behalf of the Company and authenticated by the Trustee against payment therefor by the Initial Purchasers in accordance with the terms of this Agreement and the Indenture, will be legally binding and valid
obligations of such Guarantor, enforceable against such Guarantor in accordance with its terms, except that enforceability thereof may be limited by the Enforceability Exceptions. Each Guarantee, when the Notes are issued, authenticated by the
Trustee and delivered by or on behalf of the Company, will conform in all material respects to the description thereof in the Offering Memorandum. 

(h) No Material Adverse Change. Except as otherwise disclosed in the Pricing Disclosure Package, subsequent to the respective
dates as of which information is given in Pricing Disclosure Package: (i) there has been no material adverse change, or any development that could  

  
 -3- 

 
reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, operations or prospects, whether or not arising from
transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change is called a “Material Adverse Change”); (ii) the Company and its subsidiaries, considered as one
entity, have not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary course of business; and
(iii) there has been no dividend or distribution of any kind (other than regular quarterly dividends on the Company’s Series B Convertible Perpetual Preferred Stock) declared, paid or made by the Company or, except for dividends paid to
the Company or other subsidiaries, any of its subsidiaries on any class of capital stock or repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. 

(i) Independent Accountants. To the Company’s knowledge, PricewaterhouseCoopers LLP, who has expressed its opinion with respect to
the financial statements (which term as used in this Agreement includes the related notes thereto) and supporting schedules included in the Offering Memorandum, is (i) an independent public or certified public accountant as required by the
Securities Act and the Exchange Act, (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X and (iii) a registered public accounting firm as defined by the Public
Company Accounting Oversight Board (the “PCAOB”) whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. 

(j) Preparation of the Financial Statements. The financial statements and supporting schedules included in the Offering Memorandum
present fairly the consolidated financial position of the Company and its subsidiaries (or its applicable subsidiaries) as of and at the dates indicated and the results of their operations and cash flows for the periods specified in conformity with
generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The financial data set forth in the Offering
Memorandum under the caption “Summary Consolidated Financial Information” fairly present the information set forth therein on a basis consistent with that of the audited financial statements included in the Offering Memorandum. To the
Company’s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or
otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data included in the Offering Memorandum. The interactive data in eXtensible Business Reporting Language included in each of the
Preliminary Offering Memorandum, the Pricing Disclosure Package and the Final Offering Memorandum fairly presents in all material respects the information called for by and is prepared in all material respects in accordance with the Securities and
Exchange Commission’s (the “Commission”) rules and guidelines applicable thereto. 
 (k) Company’s Accounting
System. Except as otherwise disclosed in the Offering Memorandum, the Company makes and keeps accurate books and records and maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as
applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is
compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

  
 -4- 

 (l) Incorporation and Good Standing of the Company and its Subsidiaries. Each of the
Company and its subsidiaries has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its
incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Offering Memorandum and, in the case of each Issuer, to enter into and
perform its obligations under this Agreement. Each of the Company and the subsidiaries of the Company set forth on Schedule B attached hereto (each a “Subsidiary” and, collectively, the “Subsidiaries”) is
duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, result in a Material Adverse Change. Each “significant subsidiary” (as such term
is defined in Rule 1-02 of Regulation S-X) of the Company is set forth on Schedule B attached hereto. All of the issued and outstanding capital stock or other equity or ownership interests of each Subsidiary wholly owned by the Company or any
other Subsidiary have been duly authorized and validly issued, are (in the case of capital stock) fully paid and non-assessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage,
pledge, lien, encumbrance or adverse claim other than (A) the security interests created by that certain Credit Agreement, dated as of June 30, 2011, as amended, among, inter alia, the Company, the lenders party thereto and General
Electric Capital Corporation as administrative agent, including any notes, guarantees, collateral and security documents, instruments and agreements executed in connection therewith, and including any documents entered into in connection with the
refinancing thereof as described in the Pricing Disclosure Package and the Final Offering Memorandum (the “Senior Credit Documents”) and (B) any other liens or security interests permitted by the Senior Credit Documents. The
Company does not own or control, directly or indirectly, any corporation, association or other entity other than (i) the subsidiaries listed in Exhibit 21.1 to the Company’s Annual Report on Form 10-K, as amended, for the fiscal year ended
December 31, 2014 and the subsidiaries listed in Schedule B attached hereto and (ii) such other entities omitted from Exhibit 21.1 to the Company’s Annual Report on Form 10-K,
as amended, for the fiscal year ended December 31, 2014 or Schedule B attached hereto which, when such omitted entities are considered in the aggregate as a single subsidiary, would not constitute a “significant subsidiary”
within the meaning of Rule 1-02(w) of Regulation S-X. All subsidiaries of the Company that are guarantors of the Senior Credit Documents and organized under the laws of a state of the United States are
Guarantors, other than SPDH, Inc. 
 (m) Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding
capital stock of the Company is as set forth in the Offering Memorandum in the Company’s balance sheet as of March 31, 2015 (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the Offering
Memorandum or upon the exercise of outstanding options or warrants described in the Offering Memorandum). All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and
non-assessable and have been issued in compliance with federal and state securities laws. None of the outstanding equity interests of the Company was issued in violation of any preemptive rights, rights of first refusal or other similar rights to
subscribe for or purchase securities of the Company. All outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any
capital stock of the Company are as set forth and accurately and fairly described, in all material respects, in the Offering Memorandum. The description of the Company’s stock option, stock bonus and other stock plans or arrangements, and the
options or other rights granted thereunder, set forth in the Offering Memorandum accurately and fairly presents, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. 

  
 -5- 

 (n) Non-Contravention of Existing Instruments; No Further Authorizations or Approvals
Required. Neither the Company nor any of its subsidiaries is in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational document, as applicable, or is in default (or, with the giving of notice
or lapse of time, would be in default) (“Default”) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which the Company or any of its subsidiaries is a party or by which
it or any of them may be bound (including, without limitation, any credit agreement, indenture, pledge agreement, security agreement or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness of the Company or
any of its subsidiaries), or to which any of the property or assets of the Company or any of its subsidiaries is subject (each, an “Existing Instrument”), except for such Defaults as would not, individually or in the aggregate,
result in a Material Adverse Change. The Issuers’ execution, delivery and performance of this Agreement and the Indenture, the consummation by the Issuers of the Transactions contemplated hereby and by the Offering Memorandum and the issuance
and sale of the Securities to be sold by the Issuers (i) have been duly authorized by all necessary corporate or other organizational action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement
or operating agreement or similar organizational document of the Company or any subsidiary, as applicable, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or
result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument (other than requiring
the consent of General Electric Capital Corporation as administrative agent under the respective Senior Credit Documents) and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree
applicable to the Company or any subsidiary, except, with respect to clauses (ii) and (iii), for such conflicts, breaches, Defaults, Debt Repayment Triggering Events, liens, charges, encumbrances or violations as would not, individually or in
the aggregate, result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Issuers’
execution, delivery and performance of this Agreement and the consummation by the Issuers of the Transactions contemplated hereby and by the Offering Memorandum, except (1) such as have been obtained or made by the Company or the Trustee and
are in full force and effect under the Securities Act or the Trust Indenture Act, (2) such as may be required under applicable state securities or blue sky laws and (3) such as may be required from the Financial Industry Regulatory
Authority (“FINRA”). As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other
evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. 

(o) No Material Actions or Proceedings. Except as otherwise disclosed in the Offering Memorandum, there are no legal or governmental
actions, suits or proceedings pending or, to the Company’s knowledge, threatened (i) against or affecting the Company or any of its subsidiaries, (ii) which have as the subject thereof any officer or director of, or property owned or
leased by, the Company or any of its subsidiaries or (iii) relating to environmental or discrimination matters, where in any such case (A) any such action, suit or proceeding, if determined adversely to the Company, such subsidiary or such
officer or director, would reasonably be expected to result in a Material Adverse Change or, individually or in the aggregate, adversely affect the consummation of the transactions contemplated by this Agreement or (B) any such action, suit or
proceeding is or would be material in the context of the sale of Securities. No material labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the Company’s knowledge, is threatened or imminent. 

  
 -6- 

 (p) Intellectual Property Rights. To the Company’s knowledge, the Company owns,
possesses or can acquire on reasonable terms sufficient trademarks, servicemarks, trade names, patents, copyrights, and any registrations and applications for any of the foregoing, domain names, licenses, approvals, trade secrets, know-how,
inventions, technology and other similar rights (collectively, “Intellectual Property Rights”) reasonably necessary to conduct its business as now conducted and as proposed to be conducted as set forth in the Offering Memorandum
(the “Business”). The operation of the Business by the Company, together with the Company’s use of the Intellectual Property Rights purported to be owned by, or exclusively licensed to, the Company and used by the Company in
the Business (collectively, “Company Intellectual Property Rights”), does not infringe, misappropriate or otherwise violate the Intellectual Property Rights of any third party, other than the rights of any third party under any
patent, and to the Company’s knowledge, the operation of the Business, together with the Company’s use of any Company Intellectual Property Rights, does not infringe or otherwise violate the rights of any third party under any patent.
Except as disclosed in the Offering Memorandum, no actions, suits, claims or proceedings have been asserted or, to the knowledge of the Company, threatened against the Company alleging any of the forgoing or seeking to challenge, deny or restrict
the operation of the Business by the Company, except for such actions, suits, claims or proceedings as would not, individually or in the aggregate, result in a Material Adverse Change. The Company has not received any written notice of a claim of
infringement, misappropriation or conflict with Intellectual Property Rights of others, except for such claims, individually or in the aggregate, as would not result in a Material Adverse Change. Except as disclosed in the Offering Memorandum or
except as would not, individually or in the aggregate, be reasonably expected to result in a Material Adverse Change, no court, administrative body or arbitral body has issued any order, judgment, decree or injunction restricting the operation of
the Business by the Company. 
 Except as disclosed in the Offering Memorandum or except as would not, individually or in the aggregate, be
reasonably expected to result in a Material Adverse Change, the Company Intellectual Property Rights owned by the Company and, to the knowledge of the Company, any Intellectual Property Rights exclusively licensed to the Company have not been
adjudged invalid or unenforceable, in whole or in part, and, except as aforesaid, there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property Rights. Except as disclosed in the Offering Memorandum or except as would not, individually or in the aggregate, be reasonably expected to result in a Material Adverse Change, there is no pending or, to the knowledge of the
Company, threatened action, suit, proceeding or claim by others challenging the Company’s right in or to any Company Intellectual Property Rights. Except as otherwise disclosed in the Offering Memorandum, the Company is not a party to or bound
by any agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Offering Memorandum. None of the technology or intellectual property included in, or that is the subject matter
of, the Company Intellectual Property Rights has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors or employees. 

Other than the patent applications acquired by the Company from a third party (the “Acquired Patent Applications”), the
Company has duly filed or caused to be filed with the U.S. Patent and Trademark Office (the “PTO”) or foreign and international patent authorities all patent applications disclosed in the Offering Memorandum as owned by the Company
(the “Company Patent Applications”). The Company has complied with the PTO’s duty of candor and disclosure for the Company Patent Applications and has made no material misrepresentation during prosecution of the Company Patent
Applications and the Acquired Patent Applications. To the Company’s knowledge, the Company Patent Applications disclose patentable subject matters and correctly name the inventors of the claimed subject matter. With respect to the Company
Patent Applications, the Company has not been notified of any inventorship challenges nor has any interference been declared. 

  
 -7- 

 The Company has used reasonable security measures, but in no event less than those efforts that
would accord with normal industry practice, to maintain the confidentiality of the trade secrets and other confidential information included in the Company Intellectual Property Rights. To the knowledge of the Company, all material trade secrets
included in the Company Intellectual Property Rights are valid and protectible. Furthermore, to the knowledge of the Company, (i) there has been no misappropriation of any material trade secrets included in the Company Intellectual Property
Rights by any other person, (ii) no employee, independent contractor or agent of the Company has misappropriated any trade secrets of any other person in the course of performance as an employee, independent contractor or agent of the Company,
and (iii) no employee, independent contractor or agent of the Company is in material default or breach of any term of any employment agreement, nondisclosure agreement, assignment of invention agreement or similar agreement or contract relating
in any way to the protection, ownership, development, use or transfer of Company Intellectual Property Rights owned by the Company. 
 (q)
All Necessary Permits, etc. The Company and each subsidiary possess such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their
respective businesses, and neither the Company nor any subsidiary has received, or has any reason to believe that it will receive, any notice of proceedings relating to the revocation or modification of, or noncompliance with, any such certificate,
authorization or permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, could result in a Material Adverse Change. 

(r) Title to Properties. Except as otherwise disclosed in the Offering Memorandum, each of the Company and its subsidiaries has good
and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section l(i)(k) above (or elsewhere in the Offering Memorandum), in each case free and clear of any security
interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as do not materially and adversely affect the value of such property and do not materially interfere with the use made or proposed to be made of such
property by the Company or such subsidiary and except for (A) the security interests created by the Senior Credit Documents and (B) any other liens or security interests permitted by the Senior Credit Documents. The real property,
improvements, equipment and personal property held under lease by the Company or any subsidiary are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be
made of such real property, improvements, equipment or personal property by the Company or such subsidiary. 
 (s) Tax Law
Compliance. The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar
assessment, fine or penalty levied against any of them, except for such failure to file or pay as would not, individually or in the aggregate, result in a Material Adverse Change. The Company has made adequate charges, accruals and reserves in the
applicable financial statements referred to in Section 1(i)(k) above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its consolidated subsidiaries
has not been finally determined. 
 (t) Each Issuer Not an “Investment Company”. Each Issuer has been advised of the rules
and requirements under the Investment Company Act of 1940, as amended (the “Investment  

  
 -8- 

 
Company Act”). Each Issuer is not, and will not be, either after receipt of payment for the Securities or after the application of the proceeds therefrom as described under “Use
of Proceeds” in the Offering Memorandum, an “investment company” within the meaning of the Investment Company Act. 

(u) Insurance. The Company and its subsidiaries are insured by recognized institutions with policies in such amounts and with such
deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft,
damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any subsidiary will not
be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost
that would not, individually or in the aggregate, result in a Material Adverse Change. Neither the Company nor any subsidiary has been denied any insurance coverage which it has sought or for which it has applied. 

(v) No Price Stabilization or Manipulation; Compliance with Regulation M. No Issuer has taken, directly or indirectly, any action
designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Securities or any other “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act
(“Regulation M”)) whether to facilitate the sale or resale of the Securities or otherwise, or has taken any action which would directly or indirectly violate Regulation M. 

(w) Related-Party Transactions. There are no business relationships or related-party transactions involving the Company or any
of its subsidiaries or any other person required to be described in the Offering Memorandum which have not been described as required. 

(x) Exchange Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Offering Memorandum, at the
time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Offering Memorandum, at the Closing
Date will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 (y) Statistical and Market-Related Data. The statistical, demographic and market-related data included in the Offering
Memorandum are based on or derived from sources that the Company believes to be reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources. 

(z) No Unlawful Contributions or Other Payments; Foreign Corrupt Practices Act; Anti-Bribery; Anti-Corruption. Neither the Company nor
any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, employee, agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries, (i) has made any contribution or other payment
(I) for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or (II) to any official of, or candidate for, any federal, state or foreign office, or any employee thereof, including of any
government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office, in
any such case in violation of any law, (ii) is aware of, or has taken any action, directly or indirectly, that has resulted or would result in, a violation by the Company or any of its 

  
 -9- 

 
subsidiaries of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”) or any applicable law or regulation implementing the
OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption law
(collectively, “Anti-Bribery Laws”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof
or any candidate for foreign political office, in contravention of any Anti-Bribery Laws, or (iii) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation,
any unlawful rebate, payoff, influence payment, kickback or other unlawful payment or benefit, in each case under clause (i) through (iii) that would be required to be disclosed in a registered offering of the Notes on a Form S-1
registration statement. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have instituted and maintain policies and procedures designed to promote and ensure compliance with all applicable
Anti-Bribery Laws. 
 (aa) Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial
Reporting. The Company has established and maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), which (i) are designed to ensure that material
information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in
which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness as of a date within 90 days prior to the earlier of the date that the Company filed its most
recent annual or quarterly report with the Commission and the date of the Pricing Disclosure Package; and (iii) except as otherwise disclosed in the Offering Memorandum, are effective in all material respects to perform the functions for which
they were established. Except as otherwise disclosed in the Offering Memorandum, (i) there has not been and is no material weakness in the Company’s internal control over financial reporting since January 1, 2014, and since
December 31, 2014, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting. The Company is not aware of any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. The principal executive officers (or
their equivalents) and principal financial officers (or their equivalents) of the Company have made all certifications required by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and any related rules and regulations promulgated
by the Commission. 
 (bb) Compliance with Environmental Laws. Except as described in the Offering Memorandum and except as would
not, individually or in the aggregate, result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes,
toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations and 

  
 -10- 

 
approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (iii) there are no pending or, to the Company’s knowledge, threatened
administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and
(iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting
the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws. 
 (cc) ERISA Compliance. The
Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively,
“ERISA”)) established or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with
respect to the Company or a subsidiary, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder
(the “Code”) of which the Company or such subsidiary is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any “employee benefit plan”
established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee
benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to
incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each “employee benefit plan”
established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which
would cause the loss of such qualification. 
 (dd) Broker. Except as described in the section entitled “Plan of
Distribution” in the Offering Memorandum, there are no contracts, agreements or understandings between the Issuer or any Subsidiary and any other person other than the Initial Purchasers pursuant to this Agreement that would give rise to a
valid claim against the Issuer, any such Subsidiary or any Initial Purchaser for a brokerage commission, finder’s fee or like payment in connection with the issuance, purchase and sale of the Notes. 

(ee) Regulation S Compliance. None of the Issuers nor, to the Company’s knowledge, any of their affiliates, or any person acting
on behalf of any of the foregoing persons (other than any Initial Purchaser, as to whom the Issuers make no representation), is engaged in any directed selling effort with respect to the Securities, and each of the Issuers and, to the Company’s
knowledge, their affiliates and persons acting on behalf of the foregoing persons, if any, has complied with the offering restrictions requirement of Regulation S under the Securities Act. Terms used in this paragraph have the meaning given to them
by Regulation S. 
 (ff) Affiliates of the Issuer. None of the Issuers nor, to the Company’s knowledge, any of their
affiliates (as defined in Regulation D under the Securities Act) has, directly or through any agent (other than the Initial Purchasers or any affiliate of the Initial Purchasers, as to which no representation is made), sold, offered for sale,
contracted to sell, pledged, solicited offers to buy or otherwise disposed of or negotiated in respect of, any security (as defined in the Securities Act) that is currently or will be integrated with the sale of the Securities in a manner that would
require the registration of the Notes under the Securities Act. 

  
 -11- 

 (gg) General Solicitation. No form of general solicitation or general advertising
(prohibited by the Securities Act in connection with offers or sales such as the Exempt Resales) was used by the Issuers or, to the Company’s knowledge, any of their representatives (other than any Initial Purchaser, as to whom the Issuers make
no representation) in connection with the offer and sale of any of the Notes or in connection with Exempt Resales, including, but not limited to, articles, notices or other communications published in any newspaper, magazine or similar medium or
broadcast over television or radio or the Internet, or any seminar or meeting whose attendees have been invited by any general solicitation or general advertising within the meaning of Regulation D under the Securities Act. None of the Issuers nor,
to the Company’s knowledge, any of their affiliates has entered into, and none of the Issuers nor, to the Company’s knowledge, any of their affiliates will enter into, any contractual arrangement with respect to the distribution of the
Securities except for this Agreement. 
 (hh) No Outstanding Loans or Other Extensions of Credit. Since the adoption of
Section 13(k) of the Exchange Act, neither the Company nor any of its subsidiaries has extended or maintained credit, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan, to or for any
director or executive officer (or equivalent thereof) of the Company and/or such subsidiary except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act. 

(ii) Compliance with Laws. The Company and each of its subsidiaries are conducting business in compliance with all applicable laws,
rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not, individually or in the aggregate, result in a Material Adverse Change. The Company, its subsidiaries and, to the
Company’s knowledge, the Company’s directors and officers are each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission and the New York
Stock Exchange promulgated thereunder. 
 (jj) Dividend Restrictions. Except as otherwise described in the Offering Memorandum and
except as set forth in the Senior Credit Documents, and except for any prohibitions or restrictions under applicable law, no subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from
making any other distribution with respect to such subsidiary’s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such
subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. 
 (kk) Money
Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. 
 (ll) No Conflicts with Sanctions Laws.
Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, employee, agent, affiliate or person acting on behalf of the Company or any of its subsidiaries is currently subject to any sanctions
administered by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of 

  
 -12- 

 
the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or
“blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”),
nor is the Company, any of its subsidiaries or any of the Guarantors located, organized or resident in the Balkans, Cuba, Burma (Myanmar), Iran, North Korea, Sudan, Syria, Crimea, the Central African Republic, Belarus, Ivory Coast, Democratic
Republic of the Congo, Iraq, Lebanon, Libya, Somalia, Venezuela, Yemen or Zimbabwe (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any Sanctions, to finance any business in any Sanctioned Country or in
any other manner that will result in a violation by the Company, any of its subsidiaries or any director, officer, employee, agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries of Sanctions. For the past five
years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in and will not engage in any dealings or transactions with any person that at the time of the dealing or transaction is or was, as applicable, the
subject or the target of Sanctions or with any Sanctioned Country in a manner that resulted or will result in a violation by the Company, any of its subsidiaries or any director, officer, employee, agent, affiliate or other person acting on behalf
of the Company or any of its subsidiaries of Sanctions. For the avoidance of doubt, activities by the Company and its subsidiaries pursuant to and in accordance with a general or special license to sell certain products into a Sanctioned Country
shall not be considered a breach of the foregoing representation. 
 (mm) Summaries of Certain Sections. The statements under the
headings “Material United States Federal Income Tax Consequences” and “Description of Notes” and under the subheadings “Risk Factors—Risks Relating to Our Business— If we are unable to obtain required clearances or
approvals for the commercialization of our products in the United States, we would not be able to sell those products in the United States”; —“We are subject to regulatory approval requirements of the foreign countries in which we
sell our products, and these requirements may prevent or delay us from marketing our products in those countries”; —“Our business is subject to substantial regulatory oversight and our failure to comply with applicable regulations may
result in significant costs or, in certain circumstances, the suspension or withdrawal of previously obtained clearances and approvals”; —“We are subject to healthcare fraud and abuse regulations that could result in significant
liability, require us to change our business practices and restrict our operations in the future”; and —“Healthcare reform legislation could adversely affect our revenue and financial condition” in the Offering Memorandum, under
the subheading “Business—Government Regulation” and under the heading “Item 3. Legal Proceedings” in the Company’s Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2014, fairly
summarize the matters therein described in all material respects. 
 (nn) Regulation T, U and X. Neither the issuance, sale and
delivery of the Securities nor the application of the proceeds thereof by the Company as described in the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such
Board of Governors. 
 (oo) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27 A of the
Securities Act or Section 21E of the Exchange Act) contained in the Offering Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 

(pp) Solvency. As of the date hereof and as of the Closing Date, immediately prior to and immediately following the consummation
of the issuance of the Securities, the Issuers and their  

  
 -13- 

 
Restricted Subsidiaries (as defined in the Indenture) are and will be Solvent on a consolidated basis. As used herein, “Solvent” shall mean, for any person on a particular date,
that on such date (A) the fair value of the property of such person is greater than the total amount of liabilities, including, without limitation, contingent liabilities, of such person, (B) the present fair salable value of the assets of
such person is not less than the amount that will be required to pay the probable liability of such person on its debts as they become absolute and matured, (C) such person does not intend to, and does not believe that it will, incur debts and
liabilities beyond such person’s ability to pay as such debts and liabilities mature, (D) such person is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which such person’s
property would constitute an unreasonably small capital and (E) such person is able to pay its debts as they become due and payable. 

(qq) No Registration. Assuming the accuracy of the representations and warranties of the Initial Purchasers contained in
Section 1(ii) and their compliance with their agreements set forth therein, it is not necessary to register the offer and sale of the Securities to the Initial Purchasers or the offer and sale of the Securities by the Initial Purchasers in the
manner contemplated by this Agreement, the Pricing Disclosure Package and the Final Offering Memorandum, under the Securities Act or to qualify the Indenture under the Trust Indenture Act. 

The Issuers understand that the Initial Purchasers and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant to
Section 5 hereof, counsel to the Issuers and counsel to the Initial Purchasers will rely upon the accuracy and truth of the foregoing representations, and each Issuer hereby consents to such reliance. 

Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to the Representative or to counsel for the
Initial Purchasers shall be deemed a representation and warranty by the Company to each Initial Purchaser as to the matters covered thereby. 

(ii) Each Initial Purchaser represents that it is a QIB and acknowledges that it is purchasing the Securities pursuant to a private sale
exemption from registration under the Securities Act, and that the Securities have not been registered under the Securities Act and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except
pursuant to an exemption from the registration requirements of the Securities Act. Each Initial Purchaser, severally and not jointly, represents, warrants and covenants to the Issuers that: 

(a) Neither it, nor any person acting on its behalf, has solicited or will solicit offers for, or has offered or sold or will offer or sell,
the Securities by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities
Act, and it has solicited and will solicit offers for the Securities only from, and will offer and sell the Securities only to, (1) persons whom such Initial Purchaser reasonably believes to be QIBs or, if any such person is buying for one or
more institutional accounts for which such person is acting as fiduciary or agent, only when such person has represented to such Initial Purchaser that each such account is a QIB to whom notice has been given that such sale or delivery is being made
in reliance on Rule 144A, and, in each case, in reliance on the exemption from the registration requirements of the Securities Act pursuant to Rule 144A, or (2) persons who are not U.S. persons and who are outside the United States in reliance
on, and in compliance with, the exemption from the registration requirements of the Securities Act provided by Regulation S. 
 (b) With
respect to offers and sales outside the United States, such Initial Purchaser has offered the Securities and will offer and sell the Securities (1) as part of its distribution at any time and (2) otherwise until 40 days after the later of
the commencement of the offering of the Securities and 

  
 -14- 

 
the Closing Date, only in accordance with Rule 903 of Regulation S or another exemption from the registration requirements of the Securities Act. Accordingly, neither such Initial Purchasers nor
any person acting on their behalf has engaged or will engage in any directed selling efforts (within the meaning of Regulation S) with respect to the Securities, and any such persons have complied and will comply with the offering restrictions
requirements of Regulation S. Terms used in this Section l(ii)(b) have the meanings given to them by Regulation S. 
 (c) Each Initial
Purchaser severally agrees that, at or prior to confirmation of a sale of Securities pursuant to Regulation S it will have sent to each distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases Securities
from it or through it during the restricted period a confirmation or notice to substantially the following effect: 

“The Securities covered hereby have not been registered under the United States Securities Act of 1933, as amended (the
“Securities Act”), and may not be offered or sold within the United States or to or for the account or benefit of, U.S. persons (i) as part of their distribution at any time and (ii) otherwise until forty days after the later of
the date upon which the offering of the Securities commenced and the date of closing, except in either case in accordance with Regulation S or Rule 144A under the Securities Act. Terms used above have the meanings given to them by Regulation
S.” 
 (d) Each Initial Purchaser severally agrees that it has not and will not use, authorize use of, refer to, or participate in the
planning for use of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i) the Preliminary Offering Memorandum and the Offering Memorandum; (ii) the Pricing
Disclosure Package; (iii) a written communication that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Pricing
Disclosure Package or the Offering Memorandum; (iv) any written communication prepared pursuant to Section 3(u); or (v) any written communication prepared by such Initial Purchaser and approved by the Company in advance in writing.

 The Initial Purchasers understand that the Issuers and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant
to Section 5 hereof, counsel to the Issuers and counsel to the Initial Purchasers will rely upon the accuracy and truth of the foregoing representations, and each Initial Purchaser hereby consents to such reliance. 

Section 2 Purchase, Sale and Delivery of the Securities. 

(a) Agreements to Sell and Purchase the Securities. On the basis of the representations, warranties and covenants contained in this
Agreement, the Issuers agree to issue and sell to the several Initial Purchasers, and on the basis of the representations, warranties and covenants herein contained, and upon the terms but subject to the conditions herein set forth, the Initial
Purchasers agree, severally and not jointly, to purchase from the Issuers the respective number of Securities set forth opposite their names on Schedule A. The purchase price for the Notes shall be 98.500% of their aggregate principal amount.

 (b) Delivery and Payment. Delivery of the Securities to be purchased by the Initial Purchasers and payment therefor shall be made
at the offices of White & Case LLP, 1155 Avenue of the Americas, New York, New York (or such other place as may be agreed to by the Company and the Representative) at 10:00 a.m. New York time, on June 24, 2015, or such other time and
date not later than 1:30 p.m. New York time on July 8, 2015 as the Representative and the Company shall agree in writing (the time and date of such closing are called the “Closing Date”). 

  
 -15- 

 (c) Payment for the Securities. Payment for the Securities to be sold by the
Issuers shall be made at the Closing Date by wire transfer of immediately available funds to the order of the Company. 
 It is
understood that the Representative has been authorized, for its own accounts and the accounts of the several Initial Purchasers, to accept delivery of and receipt for, and make payment of the purchase price for, the Securities. J.P. Morgan
individually and not as a Representative of the Initial Purchasers, may (but shall not be obligated to) make payment for any Securities to be purchased by any Initial Purchaser whose funds shall not have been received by the Representative by the
Closing Date for the account of such Initial Purchaser, but any such payment shall not relieve such Initial Purchaser from any of its obligations under this Agreement. 

(d) Delivery of the Securities. The Securities shall be delivered by the Issuers to the Initial Purchasers (or as the Initial
Purchasers direct) through the facilities of The Depository Trust Company against payment by the Initial Purchasers of the purchase price therefor. The Securities shall be evidenced by one or more certificates in global form registered in such names
as the Initial Purchasers may request upon at least one business day’s notice prior to the Closing Date and having an aggregate principal amount corresponding to the aggregate principal amount of the Securities. 

Section 3 Additional Covenants of the Issuers. The Issuers jointly and severally further covenant and agree with each Initial
Purchaser as follows: 
 (a) Delivery of the Preliminary Offering Memorandum, Pricing Supplement, any Issuer Written Communication
and Final Offering Memorandum. The Issuers shall furnish the Initial Purchasers and those persons identified by the Initial Purchasers, without charge, with as many copies of the Preliminary Offering Memorandum, Pricing Supplement, any Issuer
Written Communication and the Final Offering Memorandum, and any amendments or supplements thereto, as the Initial Purchasers may reasonably request. The Issuers consent to the use, in accordance with the provisions of the Securities Act and
securities or “blue sky” laws of the jurisdictions in which the Notes are offered, of the Preliminary Offering Memorandum, Pricing Supplement and the Final Offering Memorandum, and any amendments and supplements thereto required pursuant
to this Agreement, by the Initial Purchasers in connection with Exempt Resales. 
 (b) Representative’s Review of Proposed
Amendments and Supplements. As promptly as practicable following the execution and delivery of this Agreement and in any event not later than the second business day following the date hereof, the Issuers shall prepare and deliver to the Initial
Purchasers the Final Offering Memorandum, which shall consist of the Preliminary Offering Memorandum as modified only to reflect the information contained in the Pricing Supplement. Prior to amending or supplementing the Preliminary Offering
Memorandum, the Pricing Supplement or the Final Offering Memorandum (including any amendment or supplement through incorporation by reference of any report filed under the Exchange Act) and prior to the use of any Issuer Written Communication, the
Issuers shall furnish to the Representative for review, a reasonable amount of time prior to the proposed time of use thereof, a copy of each such proposed amendment or supplement or Issuer Written Communication, as the case may be, and the Issuers
shall not use any such proposed amendment or supplement or Issuer Written Communication without the Representative’s consent. 

  
 -16- 

 (c) Amendments to the Final Offering Memorandum. From the date hereof and until the later
of the Closing Date and the date that the Initial Purchasers have completed their distribution of the Securities, if any event shall occur that, in the judgment of the Issuers or in the judgment of counsel to the Initial Purchasers, makes any
statement of a material fact in the Final Offering Memorandum, as then amended or supplemented, untrue or that requires the making of any additions to or changes in the Final Offering Memorandum in order to make the statements in the Final Offering
Memorandum, as then amended or supplemented, in the light of the circumstances under which they are made, not misleading, or if it is necessary to amend or supplement the Final Offering Memorandum to comply with all applicable laws, the Issuer shall
promptly notify the Initial Purchasers of such event and (subject to Section 3(b)) prepare an appropriate amendment or supplement to the Final Offering Memorandum so that (i) the statements in the Final Offering Memorandum, as amended or
supplemented, will, in the light of the circumstances at the time that the Final Offering Memorandum is delivered to prospective Eligible Purchasers, not be misleading and (ii) the Final Offering Memorandum will comply with all applicable laws.

 (d) Pricing Supplement. The Issuers will prepare for use by the Initial Purchasers a Pricing Supplement in the form of Exhibit
B hereto reflecting the final terms of the Securities (and containing such other information as the Issuers shall deem necessary in order that the Pricing Disclosure Package shall not contain an untrue statement of a material fact or omit to
state a material fact necessary to make the statements in the Pricing Disclosure Package, in the light of the circumstances under which they were made, not misleading), in form and substance reasonably satisfactory to the Representative. The Pricing
Supplement shall constitute an Issuer Written Communication. The Issuers shall provide the Representative with copies of the Pricing Supplement a reasonable amount of time prior to such proposed use and will not use any Pricing Supplement to which
the Representative or counsel to the Initial Purchasers shall reasonably object. 
 (e) Notification upon Suspension. The Issuers
shall advise the Initial Purchasers promptly and, if requested by the Initial Purchasers, to confirm such advice in writing, of the issuance by any securities commission of any stop order suspending the qualification or exemption from qualification
of any of the Notes for offering or sale in any jurisdiction, or the initiation of any proceeding for such purpose by any securities commission or other regulatory authority. The Issuers shall use their commercially reasonable efforts to prevent the
issuance of any stop order or order suspending the qualification or exemption from qualification of any of the Notes under any securities laws, and if at any time any securities commission or other regulatory authority shall issue an order
suspending the qualification or exemption from qualification of any of the Notes under any securities laws, the Issuers shall use their commercially reasonable efforts to obtain the withdrawal or lifting of such order at the earliest possible time.

 (f) Use of Proceeds. The Company shall apply the net proceeds from the sale of the Notes sold by it in the manner described under
the caption “Use of Proceeds” in the Preliminary Offering Memorandum and the Final Offering Memorandum. 
 (g) Trustee. The
Issuers shall engage and maintain, at the Company’s expense, a trustee for the Securities. 
 (h) Investment Limitation. The
Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Securities in such a manner as would require the Issuers or any of their subsidiaries to register as an investment company under the Investment
Company Act. 

  
 -17- 

 (i) No Stabilization or Manipulation; Compliance with Regulation M. The Issuers will not
take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Securities or any other reference security, whether to facilitate the sale or resale of
the Securities or otherwise, and the Issuers will, and shall cause each of their affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (“Rule 102”) do not apply
with respect to the Securities or any other reference security pursuant to any exception set forth in section (d) of Rule 102, then promptly upon notice from the Representative (or, if later, at the time stated in the notice), the Issuers will,
and shall cause each of their affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. 

(j) Conditions Precedent. The Issuers will do and perform all things required to be done and performed under this Agreement by them
prior to the Closing Date in order to satisfy all conditions precedent on their part to the delivery of the Securities. 
 (k) DTC
Book-Entry. The Issuers will comply with their obligations under the letter of representations to DTC relating to the approval of the Securities by DTC for “book-entry” transfer and to use their best efforts to obtain approval of the
Securities by DTC for “book-entry” transfer. 
 (l) Financial Statements. Prior to the Closing Date, the
Company will furnish without charge to the Initial Purchasers, (i) as soon as they have been prepared by the Company, a copy of any regularly prepared internal financial statements of the Company and the Subsidiaries for any period subsequent
to the period covered by the financial statements appearing in the Pricing Disclosure Package and the Final Offering Memorandum, (ii) all other reports and other communications (financial or otherwise) that the Company mails or otherwise makes
available to its security holders and (iii) such other information as the Initial Purchasers shall reasonably request. 

(m) No Integration. The Issuers will not, and will not permit any of their subsidiaries to, sell, offer for sale or solicit
offers to buy any security (as defined in the Securities Act) that would be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities to the Initial Purchasers
or any Eligible Purchasers. 
 (n) No Resales. The Issuers will not, and will not permit any of their subsidiaries to, and
will use their commercially reasonable efforts to cause their other affiliates (as defined in Rule 144 under the Securities Act) not to, resell any of the Securities that have been reacquired by any of them. 

(o) No General Solicitation. The Issuers will not engage, and will not allow any of their subsidiaries to engage, and will use their
commercially reasonable efforts to cause their other affiliates and any person acting on their behalf (other than, in any case, the Initial Purchasers and any of their affiliates, as to whom the Issuers make no covenant) not to engage, in any form
of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with any offer or sale of the Securities in the United States prior to six months after the Closing Date. 

(p) No Directed Selling Efforts. The Issuers will not engage, and will not allow any of their subsidiaries to engage, and will use
their commercially reasonable efforts to cause their other affiliates and any person acting on their behalf (other than, in any case, the Initial Purchasers and any of their affiliates, as to whom the Issuers make no covenant) not to engage, in any
directed selling effort with respect to the Securities, and to comply with the offering restrictions requirement of Regulation S under the Securities Act. Terms used in this paragraph have the meanings given to them by Regulation S. 

  
 -18- 

 (q) Compliance with Regulation S. The Issuers will not register any transfer of the
Securities not made in accordance with the provisions of Regulation S (unless otherwise in compliance with the Securities Act) and not, except in accordance with the provisions of Regulation S, if applicable, issue any such Securities in the form of
definitive securities in connection with the Securities offered and sold in an offshore transaction (as defined in Regulation S). 

(r) Rule 144A Disclosure. From and after the Closing Date, for so long as any of the Notes remain outstanding and are “restricted
securities” within the meaning of Rule 144(a)(3) under the Securities Act and during any period in which the Issuer is not subject to Section 13 or 15(d) of the Exchange Act, the Issuers will make available upon request the information
required by Rule 144A(d)(4) under the Securities Act to (i) any holder or beneficial owner of Notes in connection with any sale of such Notes and (ii) any prospective purchaser of such Notes from any such holder or beneficial owner
designated by the holder or beneficial owner. The Issuers will pay the expenses of preparing, printing and distributing such documents. 

(s) No Distribution of Offering Materials. The Issuers will not, and will use their commercially reasonable efforts to cause their
affiliates or anyone acting on their or their affiliates’ behalf (other than the Initial Purchasers and their affiliates, as to whom the Issuers make no covenant) not to, distribute prior to the Closing Date any offering material in connection
with the offer and sale of the Securities other than the Preliminary Offering Memorandum, the Pricing Supplement and the Final Offering Memorandum. Before communicating any Issuer Written Communication to any person other than the Initial Purchasers
and their counsel, the Company will furnish to the Representative and counsel for the Initial Purchasers a copy of such written communication for review and will not communicate to any such third party any such written communication to which the
Representative reasonably objects. 
 (t) No Registration under the Investment Company Act. During the period of one year
after the Closing Date or, if earlier, until such time as the Securities are no longer restricted securities (as defined in Rule 144 under the Securities Act), the Issuers will not be or become a closed-end investment company required to be
registered, but not registered, under the Investment Company Act of 1940, as amended. 
 (u) No Manipulation. In connection
with the offering of the Notes, until the Representative shall have notified the Issuers of the completion of the distribution of the Notes, the Issuers will not, and will use their commercially reasonable efforts to cause their affiliates (as such
term is defined in Rule 501(b) of Regulation D under the Securities Act) not to, either alone or with one or more other persons, bid for or purchase for any account in which they or any of their affiliates have a beneficial interest, and none of the
Issuers will, and the Issuers shall use their commercially reasonable efforts to cause their affiliates not to, make bids or purchases for the purpose of creating actual or apparent active trading in, or raising the price of, the Notes. 

(v) Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such
jurisdictions as the Representative shall have reasonably requested in writing on or prior to the date hereof and will continue such qualifications in effect so long as required for the offering and resale of the Securities (but in no event for more
than one year after the Closing Date); provided that neither the Company nor any of the Guarantors shall be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it
would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject. 

  
 -19- 

 The Representative, on behalf of the Initial Purchasers, may, in its sole discretion, waive in
writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance. 

Section 4 Payment of Expenses. The Issuers agree to pay all costs, fees and expenses incurred in connection with the performance
of their obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Securities (including all printing and engraving costs),
(ii) all fees and expenses of the Trustee, including fees and expenses of counsel for the Trustee, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities to the Initial
Purchasers, (iv) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, shipping and
distribution of the Preliminary Offering Memorandum, the Pricing Supplement, the Final Offering Memorandum, any Issuer Written Communication prepared by or on behalf of, used by, or referred to by the Company, and any amendments and supplements
thereto, and this Agreement, (vi) upon receipt of such evidentiary documentation as the Company shall reasonably request, reasonable attorneys’ fees and expenses incurred by the Company or the Initial Purchasers in connection with
qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if
requested by the Representative, preparing and printing a “Blue Sky Survey” or memorandum and a Canadian wrapper and any supplements thereto, advising the Initial Purchasers of such qualifications, registrations and exemptions, which fees
and expenses shall not exceed $20,000, (vii) the filing fees incident to, and the reasonable fees and expenses of counsel for the Initial Purchasers in connection with, the FINRA’s review, if any, and approval of the Initial
Purchasers’ participation in the offering and distribution of the Securities, (viii) 50% of the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing
of the offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of
any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Representative and any such
consultants, and the cost of any aircraft chartered in connection with the road show (it being understood that the Initial Purchasers shall be responsible for the other 50% of such costs and expenses), (ix) the inclusion of the Securities in
the book-entry system of The Depository Trust Company, (x) the rating of the Securities by rating agencies and (xi) the performance by the Company of its other obligations under the Note Documents. Except as provided in this
Section 4, Section 6, Section 7 and Section 8 hereof, the Initial Purchasers shall pay their own expenses, including the fees and disbursements of their counsel. 

Section 5 Conditions of the Obligations of the Initial Purchasers. The obligations of the several Initial Purchasers to purchase
and pay for the Securities as provided herein on the Closing Date shall be subject to the accuracy of the representations and warranties on the part of the Issuers set forth in Section 1(i) hereof as of the date hereof and as of the Closing
Date as though then made, to the timely performance by the Issuers of their covenants and other obligations hereunder, and to each of the following additional conditions: 

(a) Accountants’ Comfort Letter. Prior to the Applicable Time, the Representative shall have received from PricewaterhouseCoopers
LLP, independent public or certified public accountants for the Company, a letter dated the date hereof addressed to the Initial Purchasers, in form and substance satisfactory to the Representative (i) containing statements and information of
the type ordinarily included in accountants’ “comfort letters” to initial purchasers, delivered according to Statement of Auditing 

  
 -20- 

 
Standards No. 72 (or any successor bulletin), with respect to the financial statements and certain financial information of the Company contained in the Pricing Disclosure Package as of such
dates and for such periods (and the Representative shall have received an additional five conformed copies of such accountants’ letter for each of the several Initial Purchasers), and (ii) confirming that they are (A) independent
public or certified public accountants with respect to the Company as required by the Securities Act and the Exchange Act and (B) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of
Regulation S-X. 
 (b) No Material Adverse Change or Ratings Agency Change. For the period from and after the date of this
Agreement through and including the Closing Date: 
 (i) in the judgment of the Representative there shall not have
occurred any Material Adverse Change; and 
 (ii) there shall not have occurred any downgrading, nor shall any notice have
been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any
“nationally recognized statistical rating organization” as such term is defined in Section 3(a)(62) of the Exchange Act. 

(c) Opinion of Counsel for the Company. On the Closing Date the Representative shall have received the opinion of Foley Hoag LLP,
counsel for the Company, substantially in the form attached hereto as Exhibit A, dated as of such Closing Date, in form and substance satisfactory to the Representative and counsel to the Initial Purchasers (and the Representative shall have
received an additional five signed copies of such counsel’s legal opinion for each of the several Initial Purchasers). On the Closing Date the Representative shall have received the opinion of local counsel in the jurisdiction of organization
of each Issuer not organized under the laws of Massachusetts, Delaware or New York, dated as of such Closing Date, in form and substance satisfactory to the Representative and counsel to the Initial Purchasers (and the Representative shall have
received an additional five signed copies of each such counsel’s legal opinion for each of the several Initial Purchasers). 
 (d)
Opinion of Counsel for the Initial Purchasers. On the Closing Date, the Representative shall have received the opinion of White & Case LLP, counsel for the Initial Purchasers, in form and substance satisfactory to the Initial
Purchasers, dated as of such Closing Date. 
 (e) Officers’ Certificate. On the Closing Date, the Representative shall have
received a written certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of the Closing Date, to the effect set forth in subsection (b)(ii) of this Section 5,
and further to the effect that: 
 (i) for the period from and including the date of this Agreement and through and including
the Closing Date, there has not occurred any Material Adverse Change; 
 (ii) the representations, warranties and covenants
of the Issuers set forth in Section 1(i) of this Agreement are true and correct with the same force and effect as though expressly made on and as of the Closing Date; 

(iii) (A) at April 30, 2015, there was no change in the capital stock, increase in long term debt, or decrease in
consolidated net current assets or stockholders’ equity of 

  
 -21- 

 
the Company and its subsidiaries on a consolidated basis as compared with amounts shown in the March 31, 2015 unaudited condensed consolidated balance sheet incorporated by reference in the
Pricing Disclosure Package, or (B) for the period from April 1, 2015 to April 30, 2015, there were no decreases, as compared to the corresponding period in the preceding year, in consolidated net sales, except in all instances under
the foregoing clauses (A) and (B) for changes, increases, or decreases that the Pricing Disclosure Package disclosed have occurred or may occur; and 

(iv) the Issuers have complied with all the agreements hereunder and satisfied all the conditions on their part to be performed
or satisfied hereunder at or prior to the Closing Date. 
 (f) Bring-down Comfort Letters. On the Closing Date, the Representative
shall have received from PricewaterhouseCoopers LLP, independent public or certified public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representative, to the effect that they reaffirm the
statements made in the letter furnished by them pursuant to subsection (a) of this Section 5 but related to the Final Offering Memorandum, except that the specified date referred to therein for the carrying out of procedures shall be no
more than three business days prior to the Closing Date (and the Representative shall have received an additional six conformed copies of such accountants’ letter for each of the several Initial Purchasers). 

(g) Additional Documents. The Issuers and the Trustee shall have executed and delivered the Indenture and the Securities and the
Initial Purchasers shall have received copies thereof. On or before the Closing Date, the Representative and counsel for the Initial Purchasers shall have received such information, documents and opinions as they may reasonably request for the
purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or the satisfaction of any of the conditions or agreements herein contained; and all proceedings taken by the Issuers in connection with the
issuance and sale of the Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be reasonably satisfactory in form and substance to the Representative and counsel for the Initial
Purchasers. 
 If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may
be terminated by the Representative by notice to the Company at any time on or prior to the Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 4, Section 6,
Section 7 and Section 8 shall at all times be effective and shall survive such termination. 
 Section 6 Reimbursement of
Initial Purchasers’ Expenses. If this Agreement is terminated by the Representative pursuant to Section 5 or Section 10, or if the sale to the Initial Purchasers of the Securities on the Closing Date is not consummated because of
any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representative and the other Initial Purchasers (or such Initial Purchasers as
have terminated this Agreement with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representative and the Initial Purchasers in connection with the proposed purchase and
the offering and sale of the Securities, including but not limited to fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. 

  
 -22- 

 Section 7 Indemnification. 

(a) Indemnification of the Initial Purchasers. The Issuers jointly and severally agree to indemnify and hold harmless each Initial
Purchaser, its officers, directors, employees, affiliates, and each person, if any, who controls any Initial Purchaser within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred,
to which such Initial Purchaser or such officer, director, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or at common law or otherwise (including in
settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material
fact contained in the Pricing Disclosure Package, any Road Show (as defined below), any Issuer Written Communication that the Issuers have used or referred to or the Final Offering Memorandum (or any amendment or supplement thereto), or the omission
or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; or (ii) any act or failure to act or any alleged act or failure to
act by any Initial Purchaser in connection with, or relating in any manner to, the Securities or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or
based upon any matter covered by clause (i) above, provided that the Issuers shall not be liable under this clause (ii) to any Initial Purchaser, to the extent that a court of competent jurisdiction shall have determined by a final
judgment that such loss, claim, damage, liability or action resulted directly from any such acts or failures to act undertaken or omitted to be taken by such Initial Purchaser through its bad faith or willful misconduct and to reimburse each Initial
Purchaser and each such officer, director, employee and controlling person for any and all expenses (including the fees and disbursements of counsel chosen by the Representative) as such expenses are reasonably incurred by such Initial Purchaser or
such officer, director, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity
agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and
in conformity with written information furnished to the Issuers by the Representative expressly for use in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) or the Final Offering
Memorandum (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Representative to the Issuers consists of the information described in subsection (b) below. The indemnity
agreement set forth in this Section 7(a) shall be in addition to any liabilities that the Issuers may otherwise have. “Road Show” means each “road show” (as defined in Rule 433 under the Securities Act), if
any, related to the offering of the Securities contemplated hereby that is a “written communication” (as defined in Rule 405 under the Securities Act) as if this offering were a registered offering. 

(b) Indemnification of the Issuers and their Directors and Officers. Each Initial Purchaser agrees, severally and not jointly, to
indemnify and hold harmless the Issuers, each of their directors (as defined in Rule 405 under the Securities Act), each of their officers (as defined in Rule 405 under the Securities Act) and each person, if any, who controls any Issuer within the
meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which any Issuer, or any such director, officer, manager, member, partner, other person having similar positions or controlling
person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability
or expense (or actions in respect thereof as contemplated below) arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in the Pricing Disclosure Package, any Issuer Written Communication
(including, 

  
 -23- 

 
but not limited to, any Road Show) that the Issuers have used or referred to or the Final Offering Memorandum (or any amendment or supplement thereto), or arises out of or is based upon the
omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of the Pricing Disclosure Package, any such Issuer Written Communication, or the Final Offering
Memorandum, in the light of the circumstances under which they were made) not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the
Pricing Disclosure Package, such Issuer Written Communication that the Issuers have used or referred to, or the Final Offering Memorandum (or such amendment or supplement thereto), in reliance upon and in conformity with written information
furnished to the Issuers by the Representative expressly for use therein; and to reimburse the Issuers, or any such director, officer, manager, member, partner, other person having similar positions or controlling person for any and all expenses
(including the fees and disbursements of counsel chosen by them) as such expenses are reasonably incurred by any Issuer, or any such director, officer, manager, member, partner, other person having similar positions or controlling person in
connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Issuers hereby acknowledge that the only information that the Representative and the Initial Purchasers have
furnished to the Issuers expressly for use in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) or the Final Offering Memorandum (or any amendment or supplement thereto) are the
statements set forth in the third paragraph, the fourth sentence of the seventh paragraph and the first sentence of the ninth paragraph under the caption “Plan of Distribution” in the Pricing Disclosure Package and the Final Offering
Memorandum. The indemnity agreement set forth in this Section 7(b) shall be in addition to any liabilities that each Initial Purchaser may otherwise have. 

(c) Notifications and Other Indemnification Procedures. Promptly after receipt by an indemnified party under Section 7(a) or
(b) of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under Section 7(a) or (b), notify the indemnifying party in writing of the commencement
thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party, except to the extent such indemnifying party is materially prejudiced as a proximate result of such failure, from any liability which it may have
to any indemnified party for contribution under Section 8 below or otherwise under the indemnity agreement contained in Section 7(a) or (b),. In case any such action is brought against any indemnified party and such indemnified party seeks
or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered
to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action
include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of
any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select
separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such
indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel (which shall not be unreasonably withheld, delayed or conditioned), the indemnifying party or parties will not be liable to
such indemnified party under Section 7(a) or (b) for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate
counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be 

  
 -24- 

 
liable for the fees and expenses of more than one separate firm of attorneys (together with local counsel), representing the indemnified parties who are parties to such action), which counsel
(together with any local counsel) for the indemnified parties shall be selected by the Representative (in the case of counsel for the indemnified parties referred to in Section 7(a) above) or by the Company (in the case of counsel for the
indemnified parties referred to in Section 7(b) above)), (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice
of commencement of the action or (iii) the indemnifying party authorizes the indemnified party to employ separate counsel at the indemnifying party’s expense, in each of which cases the reasonable fees and expenses of counsel shall be at
the expense of the indemnifying party and shall be paid as they are incurred. 
 (d) Settlements. The indemnifying party under
this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent (such consent not to be unreasonably withheld, delayed or conditioned), but if settled with such consent or if there be a final
judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense (to the extent provided in this Section 7) by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section 7(c) hereof, the indemnifying
party agrees that it shall be liable (to the extent provided in this Section 7) for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such
indemnifying party of the aforesaid request (including documentation of such fees and expenses reasonably satisfactory to the indemnifying party) and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance
with such request (to the extent required by this Section 7) prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the
entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such
settlement, compromise or consent includes an unconditional release of such indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability on claims that are the subject matter of such action, suit or
proceeding and does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. 

Section 8 Contribution. If the indemnification provided for in Section 7 is for any reason held to be unavailable to or
otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such
indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Issuers, on the one hand, and the
Initial Purchasers, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Issuers, on the one hand, and the Initial Purchasers, on the other hand, in connection with the statements or omissions which resulted in
such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Issuers, on the one hand, and the Initial Purchasers, on the other hand, in connection with the
offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the
Issuers, and the total initial purchasers’ discounts and commissions received by the Initial Purchasers hereunder. The relative fault of the Issuers, on the one hand, and the Initial Purchasers, on the other hand,

  
 -25- 

 
shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to
information supplied by the Issuers, on the one hand, or the Initial Purchasers, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section 7(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in
Section 7(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 8; provided, however, that no additional notice shall be required with respect to any action for
which notice has been given under Section 7(c) for purposes of indemnification. 
 The Issuers and the Initial Purchasers agree that it
would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation which does not
take account of the equitable considerations referred to in this Section 8. 
 Notwithstanding the provisions of this Section 8,
no Initial Purchaser shall be required to contribute any amount in excess of the initial purchasers’ discounts and commissions received by such Initial Purchaser in connection with the Securities purchased by it. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers’ obligations to contribute
pursuant to this Section 8 are several, and not joint, in proportion to their respective purchase commitments as set forth opposite their respective names on Schedule A. For purposes of this Section 8, each officer and employee of
an Initial Purchaser and each person, if any, who controls an Initial Purchaser within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Initial Purchaser, and each director of the Issuers, each
officer of the Issuers, and each person, if any, who controls the Issuers with the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Issuers. 

Section 9 Default of One or More of the Several Initial Purchasers. If, on the Closing Date, any one or more of the several
Initial Purchasers shall fail or refuse to purchase Securities that it or they have agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but
failed or refused to purchase does not exceed 10% of the aggregate principal amount of the Securities to be purchased on such date, the Representative may make arrangements satisfactory to the Issuers for the purchase of such Securities by other
persons, including any of the Initial Purchasers, but if no such arrangements are made by the Closing Date, the other Initial Purchasers shall be obligated, severally and not jointly, in the proportions that the principal amount of Securities set
forth opposite their respective names on Schedule A bears to the aggregate principal amount of Securities set forth opposite the names of all such non-defaulting Initial Purchasers, or in such other proportions as may be specified by the
Representative with the consent of the non-defaulting Initial Purchasers, to purchase the Securities which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on such date. If, on the Closing Date, any
one or more of the Initial Purchasers shall fail or refuse to purchase Securities and the aggregate principal amount of Securities with respect to which such default occurs exceeds 10% of the aggregate principal amount of Securities to be purchased
on such date, and arrangements satisfactory to the Representative and the Issuers for the purchase of such Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party
except that the provisions of 

  
 -26- 

 
Section 4, Section 7 and Section 8 shall at all times be effective and shall survive such termination. In any such case either the Representative or the Issuers shall have the
right to postpone the Closing Date, but in no event for longer than seven days in order that the required changes, if any, to the Final Offering Memorandum or any other documents or arrangements may be effected. 

As used in this Agreement, the term “Initial Purchaser” shall be deemed to include any person substituted for a defaulting Initial
Purchaser under this Section 9. Any action taken under this Section 9 shall not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 

Section 10 Termination of this Agreement. Prior to the purchase of the Securities by the Initial Purchasers on the Closing Date
this Agreement may be terminated by the Representative by notice given to the Company if at any time (i) trading or quotation in any of the Company’s securities shall have been suspended or limited by the Commission or by any exchange, or
trading in securities generally on any exchange shall have been suspended or limited, the settlement of such trading shall have been materially disrupted or minimum or maximum prices shall have been generally established on any of such stock
exchanges by such exchange, the Commission or the FINRA; (ii) a general banking moratorium shall have been declared by any of federal, New York, or Delaware authorities; (iii) there shall have occurred any outbreak or escalation of
national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or
international political, financial or economic conditions, as in the judgment of the Representative is material and adverse and makes it impracticable or inadvisable to market the Securities in the manner and on the terms described in the Pricing
Disclosure Package and the Final Offering Memorandum or to enforce contracts for the sale of securities; (iv) in the judgment of the Representative there shall have occurred any Material Adverse Change; or (v) the Company shall have
sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representative may interfere materially with the conduct of the business and operations of the Company regardless of whether
or not such loss shall have been insured. Any termination pursuant to this Section 10 shall be without liability on the part of (a) the Issuers to any Initial Purchaser, except that the Issuers shall be obligated to reimburse the expenses
of the Representative and the Initial Purchasers pursuant to Sections 4 and 6 hereof, (b) any Initial Purchaser to the Issuers, or (c) of any party hereto to any other party except as aforesaid and except that the provisions of
Section 7 and Section 8 shall at all times be effective and shall survive such termination. 
 Section 11 No Advisory or
Fiduciary Relationship. Each of the Issuers acknowledges and agrees that (a) the purchase and sale of the Securities sold by such party pursuant to this Agreement, including the determination of the public offering price of the Securities
and any related discounts and commissions, are an arm’s-length commercial transaction between such party, on the one hand, and the several Initial Purchasers, on the other hand, (b) in connection with the offering contemplated hereby and
the process leading to such transaction each Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of such party, or its stockholders, creditors or employees, as applicable, or any other party, (c) no
Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of such party with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Initial Purchaser has advised
or is currently advising any Issuer on other matters) and no Initial Purchaser has any obligation to such party with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Initial
Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Issuers, and (e) the Initial Purchasers have not provided any legal, accounting, regulatory or tax
advice with respect to the offering contemplated hereby and such party has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. 

  
 -27- 

 Section 12 Certain Acknowledgments. The Issuers understand that each of the Initial
Purchasers is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
securities of the companies that may be the subject of the transactions contemplated by this Agreement. 
 Each Initial Purchaser, severally
and not jointly, represents and warrants to and agrees with the Issuers that: 
 (a) in relation to each Member State of the European
Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the
“Relevant Implementation Date”), it has not made and will not make an offer of Notes to the public in that Relevant Member State prior to the publication of a prospectus in relation to the Notes which has been approved by the
competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive and the 2010 PD
Amending Directive to the extent implemented, except that it may, with effect from and including the Relevant Implementation Date, make an offer of Notes to the public in that Relevant Member State at any time: 

(i) to any legal entity which is a “qualified investor” as defined in the Prospectus Directive or the 2010 PD
Amending Directive if the relevant portion has been implemented; 
 (ii) to fewer than (i) 100 natural or legal persons
per Relevant Member State (other than qualified investors as defined in the Prospectus Directive or the 2010 PD Amending Directive if the relevant provision has been implemented) or (ii) if the Relevant Member State has implemented the relevant
provision of the 2010 PD Amending Directive, 150 natural or legal persons per Relevant Member State (other than qualified investors as defined in the Prospectus Directive or the 2010 PD Amending Directive if the relevant provision has been
implemented), subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by the Issuer for any such offer; or 

(iii) in any circumstances falling within Article 3(2) of the Prospectus Directive or Article 3(2) of the 2010 PD Amending
Directive to the extent implemented, 
 provided that no such offer of securities shall require the Company or any of the Initial Purchasers to publish a
prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. 
 For the
purposes of this provision, the expression an “offer of Notes to the public,” in relation to any Notes in any Relevant Member State, means the communication in any form and by any means of sufficient information on the terms of the
offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe for the Notes, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression
“Prospectus Directive” means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU; 

  
 -28- 

 (b) it has only communicated or caused to be communicated and will only communicate or cause to
be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the “FSMA”)) received by it in connection with the issue or sale of
the Notes in circumstances in which Section 21(1) of the FSMA does not apply to the Issuers; 
 (c) it has complied and will comply
with all applicable provisions of the FSMA with respect to anything done by it in relation to the Notes in, from or otherwise involving the United Kingdom; and 

(d) it intends to comply with all applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers the
Notes or has in its possession or distributes the Pricing Disclosure Package and the Final Offering Memorandum. 
 Section 13
Representations and Indemnities to Survive Delivery. The respective indemnities, contribution obligations, agreements, representations, warranties and other statements of the Issuers, of their officers and of the several Initial Purchasers set
forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Initial Purchaser or the Issuers or any of their partners, officers or directors or any controlling person,
as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement. 

Section 14 Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and
confirmed to the parties hereto as follows: 
 If to the Representative: 

J.P. Morgan Securities LLC 
 383
Madison Avenue 
 New York, New York 10179 

Facsimile: (917) 464-0896 

Attention: Lauren Camp 
 If to the Company: 

Alere Inc. 
 51 Sawyer Road,
Suite 200 
 Waltham, Massachusetts 02453 

Facsimile: (781) 647-3939 

Attention: Chief Executive Officer 
 with a copy
to: 
 Foley Hoag LLP 
 155
Seaport Boulevard 
 Boston, Massachusetts 02210 

Facsimile: (617) 832-7000 

Attention: John D. Hancock, Esq. 
 Any party
hereto may change the address for receipt of communications by giving written notice to the others. 

  
 -29- 

 Section 15 Successors. This Agreement will inure to the benefit of and be binding
upon the parties hereto, including any substitute Initial Purchasers pursuant to Section 9 hereof, and to the benefit of the employees, officers, directors and controlling persons referred to in Section 7 and Section 8, and in each
case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Securities as such from any of the Initial Purchasers merely by reason
of such purchase. 
 Section 16 Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or
provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable,
there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. 

Section 17 Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the
State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may
be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York and the
appellate courts thereof (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a
“Related Judgment”), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above
shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified
Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. 

With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity
(whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related
Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related
Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended. 

Section 18 USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into
law October 26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company and the Guarantors, which information may include the name and address of their
respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

Section 19 General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all
prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the
same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be 

  
 -30- 

 
amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant
to benefit. The Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. 

Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 7 and the contribution provisions of Section 8, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Sections 7 and 8 hereto fairly allocate the risks in light of the ability of the parties to investigate the Issuers, their affairs and their business in order to assure that adequate disclosure has
been made in the Pricing Disclosure Package, any Issuer Written Communication (including, but not limited to, any Road Show) and the Final Offering Memorandum (and any amendments and supplements thereto), as required by the Securities Act and the
Exchange Act. 

  
 -31- 

 If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. 

 

					
	Very truly yours,
	
	ALERE INC.
		
	BY: 		 /s/ James Hinrichs

			Name:		James Hinrichs
			Title:		Chief Financial Officer and
					Executive Vice President
	
	As Guarantors:
	
	ALERE ANALYTICS, INC.
	ALERE CONNECT, LLC
	ALERE HOLDCO, INC.
	ALERE HOME MONITORING, INC.
	ALERE INFORMATICS, INC.
	ALERE INTERNATIONAL HOLDING CORP.
	ALERE NORTH AMERICA, LLC.
	ALERE SAN DIEGO, INC.
	ALERE SCARBOROUGH, INC.
	ALERE TOXICOLOGY, INC.
	ALERE TOXICOLOGY SERVICES, INC.
	ALERE US HOLDINGS, LLC
	AMEDITECH INC.
	ATS LABORATORIES, INC.
	AVEE LABORATORIES INC.
	BIOSITE INCORPORATED
	ESCREEN, INC.
	FIRST CHECK DIAGNOSTICS, LLC
	INNOVACON, INC.
	INSTANT TECHNOLOGIES, INC.
	INVERNESS MEDICAL, LLC
	IONIAN TECHNOLOGIES, LLC
	LABORATORY SPECIALISTS OF AMERICA, INC.
	PEMBROOKE OCCUPATIONAL HEALTH, INC.
	QUALITY ASSURED SERVICES, INC.
	REDWOOD TOXICOLOGY LABORATORY, INC.
	RTL HOLDINGS, INC.
	SELFCARE TECHNOLOGY, INC.
	STANDING STONE, LLC
		
	BY:		 /s/ Jay McNamara

			Name: 		Jay McNamara
			Title:		Authorized Officer

					
	As Guarantor:
	
	GLOBAL ANALYTICAL DEVELOPMENT LLC
		
	BY:		ATS LABORATORIES, INC., ITS MANAGING MEMBER
		
	BY: 		 /s/ Jay McNamara

			Name: 		Jay McNamara
			Title:		Authorized Officer

			
	 The foregoing Purchase Agreement is hereby confirmed and accepted by the Representative in New York, New York as of the date
first above written.
  

	 J.P. MORGAN SECURITIES LLC
  

Acting as Representative of the several Initial Purchasers named in the attached Schedule A.

 
 J.P. MORGAN SECURITIES LLC

		
	By:		 /s/ Gregory Maxon

			Gregory Maxon
			Executive Director

 [Purchase Agreement Signature Page] 

 SCHEDULE A 
  

					
	 Initial Purchasers
	 	Principal
Amount of
Notes
to be Sold	 
	 J.P. Morgan Securities LLC
	 	$	170,000,000	  
	 Goldman, Sachs & Co.
	 	$	127,500,000	  
	 DNB Markets, Inc.
	 	$	42,500,000	  
	 RBC Capital Markets, LLC
	 	$	42,500,000	  
	 RBS Securities Inc.
	 	$	21,250,000	  
	 HSBC Securities (USA) Inc.
	 	$	21,250,000	  
		 	  
	  
	 
	 Total
		$	425,000,000	  

 SCHEDULE B 

Guarantors 
  

	1.	Alere Analytics, Inc. 

	2.	Alere Connect, LLC 

	3.	Alere Holdco, Inc. 

	4.	Alere Home Monitoring, Inc. 

	5.	Alere Informatics, Inc. 

	6.	Alere International Holding Corp. 

	7.	Alere North America, LLC 

	8.	Alere San Diego, Inc. 

	9.	Alere Scarborough, Inc. 

	10.	Alere Toxicology, Inc. 

	11.	Alere Toxicology Services, Inc. 

	12.	Alere US Holdings, LLC 

	13.	Ameditech Inc. 

	14.	ATS Laboratories, Inc. 

	15.	Avee Laboratories Inc. 

	16.	Biosite Incorporated 

	17.	Escreen, Inc. 

	18.	First Check Diagnostics, LLC 

	19.	Innovacon, Inc. 

	20.	Instant Technologies, Inc. 

	21.	Inverness Medical, LLC 

	22.	Ionian Technologies, LLC 

	23.	Laboratory Specialists Of America, Inc. 

	24.	Pembrooke Occupational Health, Inc. 

	25.	Quality Assured Services, Inc. 

	26.	Redwood Toxicology Laboratory, Inc. 

	27.	RTO Holdings, Inc. 

	28.	Selfcare Technology, Inc. 

	29.	Standing Stone, LLC 

 Non-Guarantor Subsidiaries 

 

	1.	Alere Switzerland GmbH 

	2.	Orgenics Ltd. 

	3.	Alere Technologies GmbH 

	4.	Alere Medical Co. Ltd. 

	5.	Inverness Medical Innovations SK, LLC 

	6.	Standard Diagnostics, Inc. 

	7.	AML Medical LLC 

	8.	Arriva Medical LLC 

	9.	Alere International Limited 

	10.	Alere AS Holdings Limited 

	11.	Axis-Shield Ltd. 

	12.	Axis-Shield AS 

	13.	Alere Technologies 

	14.	Inverness Canadian Acquisition Corporation 

	15.	Epocal Inc. 

  
 A-1 

 Exhibit B 

Pricing Term Sheet, dated June 11, 2015 

to Preliminary Offering Memorandum, dated June 10, 2015 

Strictly Confidential 

Alere Inc. 
 This pricing term sheet is
qualified in its entirety by reference to the Preliminary Offering Memorandum (the “Preliminary Offering Memorandum”). The information in this pricing term sheet supplements the Preliminary Offering Memorandum and updates and supersedes
the information in the Preliminary Offering Memorandum to the extent it is inconsistent with the information in the Preliminary Offering Memorandum. Terms used and not defined herein have the meanings assigned in the Preliminary Offering Memorandum.

 The notes have not been registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction. The notes may not be
offered or sold in the United States or to U.S. persons (as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act. Accordingly, the notes are being offered only
(1) to “qualified institutional buyers” as defined in Rule 144A under the Securities Act and (2) outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. 

 

					
	Issuer:	 	Alere Inc.	 	
	Security description:	 	6.375% Senior Subordinated Notes due 2023
	Distribution:	 	144A / Regulation S – without Registration Rights
	Size:	 	$425,000,000
	Gross proceeds:	 	$425,000,000
	Maturity:	 	July 1, 2023
		
	Coupon:	 	6.375%
	Issue price:	 	100.000% of face amount
	Yield to maturity:	 	6.375%
	Spread to Benchmark Treasury:	 	+410 basis points
	Benchmark Treasury:	 	UST 1.75% due May 15, 2023
		
	Interest Payment Dates:	 	January 1 and July 1, commencing January 1, 2016
		
	Equity clawback:	 	Up to 35% at 106.375% prior to July 1, 2018
	Optional redemption:	 	Make-whole call @ T+50bps prior to July 1, 2018, then:
			
	 	 	 On or after:
	 	 Price:

		 	July 1, 2018	 	104.781%
		 	July 1, 2019	 	103.188%
		 	July 1, 2020	 	101.594%
		 	July 1, 2021 and thereafter	 	100.000%
		
	Change of control:	 	Putable at 101% of principal plus accrued and unpaid interest
		
	Trade date:	 	June 11, 2015
	Settlement:	 	T+9; June 24, 2015. It is expected that delivery of the notes will be made against payment therefor on or about June 24, 2015, which is the ninth business day following the date hereof (such settlement cycle being
referred to as “T+9”). Under Rule 15c6-1 under the

					
			Exchange Act, trades in the secondary market generally are required to settle in three business days unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on
the date of pricing or the next five business days will be required, by virtue of the fact that the notes initially will settle in T+9, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement.
Purchasers of the notes who wish to trade the notes on the date of pricing or the next five business days should consult their own advisors.
		
	CUSIP (Rule 144A / Reg S):		01449J AM7 / U01457 AD9
	ISIN (Rule 144A / Reg S):		US01449JAM71 / USU01457AD95
	Denominations/Multiple:		$2,000 x $1,000
	Ratings*:		Caa1/CCC+
		
	Joint Book-Running Managers:		J.P. Morgan
			Goldman, Sachs & Co.
			DNB Markets
			RBC Capital Markets
		
	Co-Managers:		RBS
			HSBC

  
 This
material is confidential and is for your information only and is not intended to be used by anyone other than you. This information does not purport to be a complete description of these notes or the offering. Please refer to the Preliminary
Offering Memorandum for a complete description. 
 This communication is being distributed in the United States solely to Qualified Institutional
Buyers, as defined in Rule 144A under the Securities Act of 1933, as amended, and outside the United States solely to Non-U.S. persons as defined under Regulation S. 

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it
is unlawful to make such offer or solicitation in such jurisdiction. 
  

	*	A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. 

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. 

  
 2exhibit10-1.htm

 

 

EXHIBIT 10.1

ADVISORY AGREEMENT

 

 

Advisory Agreement dated as of June 1, 2105 by and among ISMO Tech Solutions, Inc. (“Company”), and Ari Jatwes or his incorporated company (the “Advisor”).

 

W I T N E S S E T H:

 

The Company desire to engage the services of the Advisor for purposes of general business analysis and development and more specifically for those services set forth below (collectively, the “Advisory Services”).

 

Advisor is desirous of performing the Advisory Services on behalf of the Company and desires to be engaged and retained by the Company for such purposes.

 

Accordingly, in consideration of the recitals, promises and conditions in this Agreement, the Advisor and the Company agree as follows:

 

1.           Advisory Services.  The Company hereby retains the Advisor to provide expertise in the areas of public company administration, finance and corporate development to the Company’s management and board of directors, and the Advisor accepts such retention all on the terms and conditions herein contained.     Specific services are:

 

(a)           to assist the Company all corporate development activities and direction;

 

	
(b)

	
to assist the Company in the implementation of new asset identification and analysis of those assets; and

 

	
(c)

	
to assist the Company in the analysis and negotiation of any financial transactions related to the licensing or acquisition of assets determined to be a strategic fit.

 

 

  

  

  

2.           Term.

 

 (a)           Subject to this Section 2(a), the initial term (the “Initial Term”) of this Agreement shall be for a one-year period commencing on June 1, 2015. The term will automatically renew unless terminated by mutual consent.

 

3.           Compensation.  The Company shall pay and deliver to the Advisor:

 

	
•

	
Monthly retainer of USD$5,000 once the Company has raised a minimum of $1,000,000 in the aggregate;

 

	
•

	
Share options as deemed appropriate by the compensation committee;

 

	
•

	
An engagement fee of 250,000 restricted common shares. Restricted shares will be subject to leak out provisions once freely tradable either by SEC rules as they pertain to insiders or if no longer applicable, to a 25% per 90-day leak-out provision, voluntarily agreed to on execution of this Agreement (“Common Shares”).

 

4.           Expenses:  The Company will reimburse Advisor for all reasonable expenses incurred during performance of duties as Advisor.

 

5.           Termination:  Either the Company or Advisor can terminate this Agreement by giving Ninety (90) days written notice.   Company agrees not to terminate (unless for cause) this Agreement during the Initial Term unless there is clear evidence the Advisor is not performing its required duties hereunder in good faith. If the Company terminates the Agreement prior to the end of the Initial Term (without cause), the Advisor shall be entitled to any outstanding unpaid portion of reimbursable expenses, if any, and for the remainder of the unexpired portion of the applicable term (Initial Term or an agreed extension period) of the Agreement.

 

6.           Duties of the Company.

 

(a)           The Company shall supply the Advisor, on a regular and timely basis, with all approved data and information about the Company, its management, its products and its operations, and the Company shall be responsible for advising the Advisor of any facts which would affect the accuracy of any prior data and information previously supplied to the Advisor so that the Advisor may take corrective action.

 

 

  

  

  

 

(b)           The Company shall promptly supply the Advisor with:  full and complete copies of all filings with all federal and state securities agencies; full and complete copies of all stockholder stock reports and communications, whether or not prepared with the Advisor’s assistance; all data and information supplied to any analyst, broker-dealer, market maker or other member of the financial community; and all product/services brochures, sales materials, etc.

 

(c)           The Company shall contemporaneously notify the Advisor if any information or data being supplied to the Advisor has not been generally released to the public.

 

(d)           Other specific obligations of the Company hereunder include the obligation to make all payments and/or deliveries of securities required hereunder (including, but not limited to the Common Shares) as due.

 

7.            Representatives and Indemnification by Company.

 

(a)           The Company shall be deemed to make a continuing representation of the accuracy of any and all material facts, information and data which it supplies to the Advisor and the Company acknowledges its awareness that the Advisor will rely on such continuing representation in disseminating such information.

 

(b)           The Advisor, in the absence of notice in writing from the Company, will rely on the continuing accuracy of material, information and data supplied by the Company.

 

(c)           The Company hereby agrees to indemnify the Advisor against, and to hold the Advisor harmless from, any claims, demands, suits, loss, damages, etc. arising out of the Advisor’s reliance on: (i) the general availability of information supplied to the Advisor and the Advisor”s ability to promulgate such information; and (ii) the accuracy and continuing accuracy of such facts, material, information and data, unless the Advisor has been negligent in fulfilling its duties and obligations hereunder.

 

8.            Representatives and Indemnification by Advisor.

 

The Advisor agrees to provide the Advisor Services hereunder in a manner consistent with the performance standards observed by other professionals undertaking such functions.

 

  

  

  

9.           Mutual Indemnification

 

Subject to the specific indemnifications found in Section 7 and 8 of this Agreement, each party shall indemnify and hold harmless the other party and its affiliates, directors, officers, employees, partners, contractors or agents, from and against any and all claims, actions, causes of action, demands, or liabilities of whatsoever kind and nature, including judgments, interest, reasonable attorneys’ fees, and all other costs, fees, expenses, and charges (collectively, “Claims”) to the extent that such Claims arise out of or were caused by the negligence, gross negligence, or willful misconduct of the indemnifying party or from any breach of the Agreement by the indemnifying party.

 

10.           Confidentiality and Other Provisions.

 

(a)           The Advisor shall not, except as authorized or required to perform the Advisor Services, reveal or divulge to any person or Company any of the trade secrets, secret or confidential operations, processes or dealings or any information concerning the organization, business, finances, transactions or other affairs of the Company, which may come to its knowledge during the term of this Agreement and shall keep in complete secrecy all confidential information entrusted to it and shall not use or attempt to use any such information in any manner which may injure or cause loss, either directly or indirectly, to each Company’s business or may be likely so to do.  This restriction shall continue to apply after the termination of this Agreement without limit in point of time but shall cease to apply to information or knowledge, which may come into the public domain.  The Advisor shall comply with such directions, as the Company shall make to ensure the safeguarding or confidentiality of all such information.

 

(b)           During the term of this Agreement, the Advisor shall devote sufficient time, attention, and ability to the business of the Company, and to any associated Company, as is reasonably necessary for the proper performance of the Advisory Services pursuant to this Agreement.   During the term of this Agreement, the Advisor shall:

 

(i)           at all times perform the Advisory Services to the best of its abilities and in the best interests of the Company; and

 

(ii)           devote such of its time, labor and attention to the business of the Company as it, in its sole discretion, deems necessary for the proper performance of the Advisor’s obligations under this Agreement; and

 

 

  

  

  

 

10.           Relationship of Parties.  The Advisor is an independent contractor, responsible for compensation of its agents, employees and representatives, as well as all applicable withholding therefrom and taxes thereon (including unemployment compensation) and all workers’ compensation insurance.  This Agreement does not establish any partnership, joint venture, or other business entity or association between the parties, and neither party is intended to have any interest in the business or property of the other.

 

11.           Miscellaneous.

 

(a)           Entire Agreement; Amendments. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters.

 

(b)           Notices.  Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this Section prior to 4:30 p.m. (Eastern Standard time) on a Business Date, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this Agreement later than 4:30 p.m. (Eastern Standard time) on any date and earlier than 11:59 p.m. (Eastern Standard time) on such date, (iii) the Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.  The address for such notices and communications shall be as follows:

 

If to the Company:

 

Address: 501 Madison Ave, 14th Floor

New York NY 10022

ATT: William Rosenstadt (Genreal Counsel) or Denis Corin (President)

Email: dcorin@qbiomed.com

 

If to the Advisor:                                

Ari Jatwes

7475 Avenida del Mar #1303

Boca Raton ,FL,33433

 

561 245 7247

 

561 843 9281 ( c)

 

Email: arijat@gmail.com

 

or such other address as may be designated in writing hereafter, in the same manner, by such party.

 

 

  

  

  

 

(c)           Amendments; Waivers.  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and the Advisor, or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it thereafter.

 

(d)           Headings.  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.  All words used in this Agreement will be construed to be of such number and gender as the circumstances require.

 

(e)           Successors and Assigns.  This Agreement is intended only for the benefit of, shall be binding upon and inure to the benefit of the parties and their respective successors.  Anything in the foregoing to the contrary notwithstanding, subject to compliance with applicable securities laws, the Advisor may assign and/or transfer all or a portion of the consideration payable by the Company hereunder.

 

(f)           Governing Law.  This Agreement shall be governed by, construed and enforced in accordance with the internal laws of the State of New York without regard to the principles of conflicts of law thereof.  Each party hereby irrevocably submits to the non-exclusive jurisdiction of the United States Federal District Court for the Southern District of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper under such court’s jurisdiction.

 

(g)           Severability.  In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

(h)           Remedies.  In addition to being entitled to exercise all rights provided herein or granted by law, including the recovery of damages, the Advisor will be entitled to specific performance of the obligations of the Company hereunder.  The Company and the Advisor agree that monetary damages would not be adequate compensation for any loss incurred by reason of any breach of its obligations described in this Agreement and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.

 

[Remainder of page intentionally left blank]

 

 

  

  

  

 

 IN WITNESS WHEREOF, the parties have hereunto set their hands and seals the day and year first above written.

 

 

 

X         /s/ Ari Jatwes

Advisor

 

X        /s/ Denis Corin

President QBioMed Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]